急性冠脉综合征预防进展
来源:岁月联盟
时间:2010-07-12
[关键词]冠状动脉疾病动脉粥样硬化炎症急性冠脉综合征
5 其他
5.1 血小板糖蛋白IIb/IIIa受体拮抗药 血小板糖蛋白IIb/II
Ia受体拮抗药抑制了血小板聚集的最后共同途径。在急性冠脉综合征的预防中,
血小板糖蛋白IIb/IIIa受体拮抗药可抑制血小板聚集和血栓形成,使冠状动
脉保持通畅。血小板糖蛋白IIb/IIIa受体拮抗药的优点是:(1)抗血小板作
用强。(2)不良反应少,严重出血不良反应更少。(3)有静脉、口服2种制剂,使用较
方便。(4)虽然问世时间不长,但有关的大型临床试验较多,临床证据充分。
5.2 冠状动脉内介入 冠状动脉内介入治疗是急性冠脉综合征的重要治
疗方法。在急性冠脉综合征的预防中冠状动脉内介入治疗的作用是:(1)冠状动脉内
安放支架可使该处动脉粥样硬化斑块不易破裂和脱落。(2)冠状动脉内介入治疗使
血管狭窄程度改善或消失,一旦发生动脉粥样硬化斑块破裂后血管完全阻塞的可能
性减少。预防动脉粥样硬化斑快破裂和急性冠脉综合征的发生具有十分重要的意义
。随着研究的深入,我们期待着更明确、更有效的预防急性冠脉综合征的新方法的
问世。
[]
[1]DAVIESMJ.Stabilityandinstability:th
etwofacesofcoronaryatherosclerosis.T
hePaulDudlyWhiteLecture1995[J].Circulat
ion,1996,94(8):20132020.
[2]vanderWALAC,BECKERAE,vanderLOOSCM,et
al.Siteofintimalruptureorerosionofth
rombosedcoronaryatheroscleroticplaq
ueischaracterizedbyaninflammatorypro
cessirrespectiveofthedominantplaquem
orphology[J].Circulation,1994,89(1):3644.
[3]LIBBYP.Molecularbasesoftheacutecoro
narysyndromes[J].Circulation,1995,91(11):2844
2850.
[4]SUKHOVAGK,SCHONBECKU,RABKINE,etal.Ev
idenceforincreasedcollagenolysisbyin
terstitialcollagenases1and3invulnera
blehumanatheramatousplaques[J].Circul
ation,1999,99(19):25032509.
[5]SHIGP,SUKHOVAGK,GRUBBA,etal.Cystatin
Cdeficiencyinhumanatherosclerosisan
daorticaneurysms[J].JClinInvest,1999,104(9)
:11911197.
[6]MACHF,SCHONBECKU,FABUNMIRP,etal.Tlym
phocytesinduceendothelialcellmatrix
metalloproteinaseexpressionbyaCD40Ld
ependentmechanism:implicationsfortub
uleformation[J].AmJPathol,1999,154(1):229238.
[7]DeCATERINAR,LIBBYP,PENFHB,etal.Nitri
coxidedecreasescytokineinducedendot
helialactivation.Nitricoxideselectiv
elyreducesendothelialexpressionofadh
esionmoleculesandproinflammatorycyto
kines[J].JClinInvest,1995,96(1):6068.
[8]BUSTOSC,HERNANDEZPRESAMA,ORTEGOM,et
al.HMGCoAreductaseinhibitionbyatorva
statinreducesneointimalinflammationi
narabbitmodelofatherosclerosis[J].JAm
CollCardiol,1998,32(7):20572064.
[9]RIDKERPM,RIFAIN,PFEFFERMA,etal.Longt
ermeffectsofpravastatinonplasmaconc
entrationofCreactiveprotein:theChole
sterolandRecurrentEvents(CARE)Investi
gators[J].Circulation,1999,100(3):230235.
[10]AIKAWAM,VOGLICSJ,SUGIYAMAS,etal.Diet
arylipidloweringreducestissuefactore
xpressioninrabbitatheroma[J].Circulat
ion,1999,100(11):12151222.
[11]MOULTONKS,HELLERE,KONERDINGMA,etal.A
ngiogenesisinhibitorsendostatinorTN
P470reduceintimalneovascularizationa
ndplaquegrowthinapolipoproteinEdefi
cientmice[J].Circulation,1999,99(13):17261732.
[12]ENDRESM,LAUFSU,HUANGZ,etal.Strokepro
tectionby3hydroxy3methylglutaryl(HMG
)CoAreductaseinhibitorsmediatedbyend
othelialnitricoxidesynthase[J].ProcNa
tlAcadSciUSA,1998,95(15):88808885.
[13]LIBBYP.Currentconceptsofthepathoge
nesisoftheacutecoronarysyndromes[J].C
irculation,2001,104(3):365372.
[14]MARXN,MACKMANN,SCHONBECKU,etal.PPARa
lphaactivatorsinhibittissuefactorexp
ressionandactivityinhumanmonocytes[J
].Circulation,2001,103(2):213219.
[15]RUBINSHB,ROBINSSJ,COLLINSD,etal.Gemf
ibrozilforthesecondarypreventionofco
ronaryheartdiseaseinmenwithlowlevels
ofhighdensitylipoproteincholesterol
[J].NEnglJMed,1999,341(6):410418.
[16]BARROSOI,GURNELLM,CROWLEYVE,etal.Dom
inantnegativemutationsinhumanPPARgam
maassociatedwithsevereinsulinresista
nce,diabetesmellitusandhypertension[J
].Nature,1999,402(6764):880883.
[17]JIANGC,TINGAT,SEEDB.PPARgammaagonis
tsinhibitproductionofmonocyteinflamm
atorycytokines[J].Nature,1998,391(6662):8286.
[18]YUSUFS,SLEIGHTP,POGUEJ,etal.Effectso
fanangiotensinconvertingenzymeinhi
bitor,ramipril,oncardiovascularevents
inhighriskpatients[J].NEnglJMed,2000,342(3
):145153.
[19]CHENXL,TUMMALAPE,OLBRYCHMT,etal.Ang
iotensinIIinducesmonocytechemoattrac
tantprotein1geneexpressioninratvasc
ularsmoothmusclecells[J].CircRes,1998,83(9
):952959.
[20]FUKAIT,SIEGFRIEDMR,USHIOFUKAIM,etal
.Modulationofextracellularsuperoxide
dismutaseexpressionbyangiotensinIIa
ndhypertension[J].CircRes,1999,85(1):2328.
[21]KUVINJT,KIMMELSTIELCD.Infectiouscau
sesofatherosclerosis[J].AmHeartJ,1999,137(
2):216226.
|
5.1 血小板糖蛋白IIb/IIIa受体拮抗药 血小板糖蛋白IIb/II
Ia受体拮抗药抑制了血小板聚集的最后共同途径。在急性冠脉综合征的预防中,
血小板糖蛋白IIb/IIIa受体拮抗药可抑制血小板聚集和血栓形成,使冠状动
脉保持通畅。血小板糖蛋白IIb/IIIa受体拮抗药的优点是:(1)抗血小板作
用强。(2)不良反应少,严重出血不良反应更少。(3)有静脉、口服2种制剂,使用较
方便。(4)虽然问世时间不长,但有关的大型临床试验较多,临床证据充分。
5.2 冠状动脉内介入 冠状动脉内介入治疗是急性冠脉综合征的重要治
疗方法。在急性冠脉综合征的预防中冠状动脉内介入治疗的作用是:(1)冠状动脉内
安放支架可使该处动脉粥样硬化斑块不易破裂和脱落。(2)冠状动脉内介入治疗使
血管狭窄程度改善或消失,一旦发生动脉粥样硬化斑块破裂后血管完全阻塞的可能
性减少。预防动脉粥样硬化斑快破裂和急性冠脉综合征的发生具有十分重要的意义
。随着研究的深入,我们期待着更明确、更有效的预防急性冠脉综合征的新方法的
问世。
[]
[1]DAVIESMJ.Stabilityandinstability:th
etwofacesofcoronaryatherosclerosis.T
hePaulDudlyWhiteLecture1995[J].Circulat
ion,1996,94(8):20132020.
[2]vanderWALAC,BECKERAE,vanderLOOSCM,et
al.Siteofintimalruptureorerosionofth
rombosedcoronaryatheroscleroticplaq
ueischaracterizedbyaninflammatorypro
cessirrespectiveofthedominantplaquem
orphology[J].Circulation,1994,89(1):3644.
[3]LIBBYP.Molecularbasesoftheacutecoro
narysyndromes[J].Circulation,1995,91(11):2844
2850.
[4]SUKHOVAGK,SCHONBECKU,RABKINE,etal.Ev
idenceforincreasedcollagenolysisbyin
terstitialcollagenases1and3invulnera
blehumanatheramatousplaques[J].Circul
ation,1999,99(19):25032509.
[5]SHIGP,SUKHOVAGK,GRUBBA,etal.Cystatin
Cdeficiencyinhumanatherosclerosisan
daorticaneurysms[J].JClinInvest,1999,104(9)
:11911197.
[6]MACHF,SCHONBECKU,FABUNMIRP,etal.Tlym
phocytesinduceendothelialcellmatrix
metalloproteinaseexpressionbyaCD40Ld
ependentmechanism:implicationsfortub
uleformation[J].AmJPathol,1999,154(1):229238.
[7]DeCATERINAR,LIBBYP,PENFHB,etal.Nitri
coxidedecreasescytokineinducedendot
helialactivation.Nitricoxideselectiv
elyreducesendothelialexpressionofadh
esionmoleculesandproinflammatorycyto
kines[J].JClinInvest,1995,96(1):6068.
[8]BUSTOSC,HERNANDEZPRESAMA,ORTEGOM,et
al.HMGCoAreductaseinhibitionbyatorva
statinreducesneointimalinflammationi
narabbitmodelofatherosclerosis[J].JAm
CollCardiol,1998,32(7):20572064.
[9]RIDKERPM,RIFAIN,PFEFFERMA,etal.Longt
ermeffectsofpravastatinonplasmaconc
entrationofCreactiveprotein:theChole
sterolandRecurrentEvents(CARE)Investi
gators[J].Circulation,1999,100(3):230235.
[10]AIKAWAM,VOGLICSJ,SUGIYAMAS,etal.Diet
arylipidloweringreducestissuefactore
xpressioninrabbitatheroma[J].Circulat
ion,1999,100(11):12151222.
[11]MOULTONKS,HELLERE,KONERDINGMA,etal.A
ngiogenesisinhibitorsendostatinorTN
P470reduceintimalneovascularizationa
ndplaquegrowthinapolipoproteinEdefi
cientmice[J].Circulation,1999,99(13):17261732.
[12]ENDRESM,LAUFSU,HUANGZ,etal.Strokepro
tectionby3hydroxy3methylglutaryl(HMG
)CoAreductaseinhibitorsmediatedbyend
othelialnitricoxidesynthase[J].ProcNa
tlAcadSciUSA,1998,95(15):88808885.
[13]LIBBYP.Currentconceptsofthepathoge
nesisoftheacutecoronarysyndromes[J].C
irculation,2001,104(3):365372.
[14]MARXN,MACKMANN,SCHONBECKU,etal.PPARa
lphaactivatorsinhibittissuefactorexp
ressionandactivityinhumanmonocytes[J
].Circulation,2001,103(2):213219.
[15]RUBINSHB,ROBINSSJ,COLLINSD,etal.Gemf
ibrozilforthesecondarypreventionofco
ronaryheartdiseaseinmenwithlowlevels
ofhighdensitylipoproteincholesterol
[J].NEnglJMed,1999,341(6):410418.
[16]BARROSOI,GURNELLM,CROWLEYVE,etal.Dom
inantnegativemutationsinhumanPPARgam
maassociatedwithsevereinsulinresista
nce,diabetesmellitusandhypertension[J
].Nature,1999,402(6764):880883.
[17]JIANGC,TINGAT,SEEDB.PPARgammaagonis
tsinhibitproductionofmonocyteinflamm
atorycytokines[J].Nature,1998,391(6662):8286.
[18]YUSUFS,SLEIGHTP,POGUEJ,etal.Effectso
fanangiotensinconvertingenzymeinhi
bitor,ramipril,oncardiovascularevents
inhighriskpatients[J].NEnglJMed,2000,342(3
):145153.
[19]CHENXL,TUMMALAPE,OLBRYCHMT,etal.Ang
iotensinIIinducesmonocytechemoattrac
tantprotein1geneexpressioninratvasc
ularsmoothmusclecells[J].CircRes,1998,83(9
):952959.
[20]FUKAIT,SIEGFRIEDMR,USHIOFUKAIM,etal
.Modulationofextracellularsuperoxide
dismutaseexpressionbyangiotensinIIa
ndhypertension[J].CircRes,1999,85(1):2328.
[21]KUVINJT,KIMMELSTIELCD.Infectiouscau
sesofatherosclerosis[J].AmHeartJ,1999,137(
2):216226.
下一篇:神经干细胞的研究及其应用新进展